Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.66 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928217 | 1.00 | F10 (0.66) | F10F2KLKB1 | |
| SCHEMBL4921562 | 0.97 | F10 (0.68) | F10F2KLKB1 | |
| SCHEMBL4921568 | 0.97 | F10 (0.68) | F10F2KLKB1 | |
| SCHEMBL4175322 | 0.96 | F10 (0.70) | F10F2KLKB1 | |
| SCHEMBL4175326 | 0.96 | F10 (0.70) | F10F2KLKB1 | |
| SCHEMBL4179365 | 0.93 | F10 (0.73) | F10F2KLKB1 | |
| SCHEMBL4179358 | 0.93 | F10 (0.73) | F10F2KLKB1 | |
| SCHEMBL4172775 | 0.86 | F10 (0.67) | F10 | |
| SCHEMBL4172777 | 0.86 | F10 (0.67) | F10 | |
| SCHEMBL4929194 | 0.85 | F10 (0.66) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | TFPI, TPSAB1, TFPI2 | F10 24/4885F2 10/4885KLKB1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.